14. An injectable oligomer-polymer composition, consisting of a combination of at least two biologically degradable inert materials and at least one biologically active ingredient, and wherein at least one of the at least two biologically degradable inert materials comprises an oligomeric ester of at least one hydroxycarboxylic acid and at least one other of the at least two biologically degradable inert materials comprises a polymeric ester of at least one hydroxycarboxylic acid.

15. The oligomer-polymer composition as defined in claim 14, wherein the at least two biologically degradable inert materials are polymerization products of identical or different hydroxycarboxylic acids.

16. The oligomer-polymer composition as defined in claim 14, wherein each of the at least two biologically degradable inert materials is a different polymerization product of hydroxycarboxylic acid monomers and each of said hydroxycarboxylic acid monomers of each of said polymerization product is selected from the group consisting of lactic acid and glycolic acid.

17. The oligomer-polymer composition as defined in claim 14, wherein at least one of the at least two biologically degradable inert materials is a liquid oligomer and another of the at least two biologically degradable inert materials is a solid polymer, said solid polymer having a molecular weight that is greater than that of said liquid oligomer.

18. The oligomer-polymer composition as defined in claim 17, wherein the liquid oligomer is of formula I, II or III



I

B6



II



III

wherein R is the same or different in monomer units of the formula I, II or III that are identified by m, n, o, p, q and r and R represents

$-CH_2-$, $-CH(CH_3)-$, $-(CH_2)_5-$, $-CH_2-CH_2-O-CH_2-$, $-CH_2-CH_2-O-CH_2-CH_2-O-CH_2-$ or homologs thereof each with up to 5 further carbon atoms;

R_1 represents $-CH_2-COOY$, $-CH(CH_3)-COOY$, $-CH_2-CH_2-COOY$, $-CH_2-CH_2-CH_2COOY$, $-CH_2-CH_2-CH_2-CH_2-COOY$, $-CH_2-CH_2-CH_2-CH_2-CH_2-COOY$, $-CH_2CH(CH_3)-Y$, -(cyclo-C_6H_{11}) or $-CH_2-C_6H_5$;

R_2 represents $-CH_2-CH(CH_3)-$, $-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-CH_2-CH_2-$, $-(CH_2)_2-O-(CH_2)_2-O-(CH_2)_2-$, $-(CH_2)_2-O-(CH_2)_2-O-(CH_2)_2-O-(CH_2)_2-$, $-(CH_2)_2-O-(CH_2)_2-O-(CH_2)_2-O-(CH_2)_2-O-(CH_2)_2-$, $-CH_2-CH(-Y)-CH_2-$, cyclohexane-1,2-diyl, cyclohexane-1,3-diyl or cyclohexane-1,4-diyl;

R_3 represents $(-CH_2)_2CH-$, $(-CH_2)_3-CH_3$ or $(-CH_2)_3C-CH_2-CH_3$;

Y represents -H, $-CH_3$, $-C_2H_5$, $-C_3H_7$ or $-C_4H_9$, and

wherein m, n, o, p, q and r, independently of one another, are each a whole number from 2 to 18.

19. The oligomer-polymer composition as defined in claim 18, wherein said R is said $-CH(CH_3)-$, said R_1 is said $-CH(CH_3)-COOY$, said Y is said $-C_2H_5$ and said m, n, o, p, q or r is an integer from 2 to 4.

20. The oligomer-polymer composition as defined in claim 17, wherein the liquid oligomer is selected from the group consisting of poly-(L-lactides), poly-(D,L-

lactides), polyglycolides, poly-(caprolactones), poly(dioxanones), poly-(hydroxybutyric acids), poly-(hydroxyvaleric acids) and poly-(glycosalicylates), or mixtures thereof, or copolymers thereof made by a process comprising ring opening polymerization of lactones in the presence of a biocompatible starter molecule, and wherein said lactones are selected from the group consisting of L-lactide, D,L-lactide, glycolide, p-dioxanone and e-caprolactone and said biocompatible starter molecule is an aliphatic or cycloaliphatic compound with one or more free hydroxyl groups.

B6

21. The oligomer-polymer composition as defined in claim 20, wherein said biocompatible starter molecule is an alkyl L-lactate, cholesterol, 1,2-dihydroxy-propane, triethyleneglycol, glycerol or pentaerythritol.

22. The oligomer-polymer composition as defined in claim 17, wherein the solid polymer and the liquid oligomer are present in a ratio of said solid polymer to said liquid oligomer of 1:100 to 1:1.

23. The oligomer-polymer composition as defined in claim 22, wherein said ratio is from 1:10 to 1:2.

24. The oligomer-polymer composition as defined in claim 14, wherein the biologically active ingredient is selected from the group consisting of hormones, immune modulators, immune suppressive agents, antibiotics, cytostatic agents,

diuretics, gastrointestinal drugs, cardiovascular drugs and neuropharmacological drugs.

25. The oligomer-polymer composition as defined in claim 24, wherein the biologically active ingredient is present in dissolved or suspended form in the inert materials.

B6

26. The oligomer-polymer composition as defined in claim 14, in the form of an injectable material, which, when injected, forms a coagulate under the influence of body fluid.

27. An injectable implant, obtainable by injecting an oligomer-polymer composition into a body, wherein said oligomer-polymer composition comprises a combination of at least two biologically degradable inert materials and at least one biologically active ingredient, and wherein at least one of the at least two biologically degradable inert materials comprises an oligomeric ester of at least one hydroxycarboxylic acid and at least one other of the at least two biologically degradable inert materials comprises a polymeric ester of hydroxycarboxylic acids.

28. An injectable implant, obtainable by injecting an oligomer-polymer composition into a body, wherein said oligomer-polymer composition comprises